Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) in patients with moderate COPD: Results from the CRYSTAL study

被引：0
|
作者：
Greulich, Timm
Kostikas, Konstantinos
Gaga, Mina
Aalamian-Mattheis, Maryam
Patalano, Francesco
Nunez, Xavier
Pagano, Veronica Anna
Clemens, Andreas
Fogel, Robert
Vogelmeier, Claus F.
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.PA1801
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA1801
引用
收藏
页数：1
相关论文
共 50 条
  • [1] INDACATEROL/GLYCOPYRRONIUM REDUCES THE RISK OF CLINICALLY IMPORTANT DETERIORATION IN PATIENTS WITH MODERATE COPD: RESULTS FROM THE CRYSTAL STUDY
    Greulich, Timm
    Kostikas, Konstantinos
    Gaga, Mina
    Aalamian-Mattheis, Maryam
    Patalano, Francesco
    Nunez, Xavier
    Pagano, Veronica Anna
    Clemens, Andreas
    Fogel, Robert
    Vogelmeier, Claus F.
    RESPIROLOGY, 2017, 22 : 179 - 180
  • [2] INDACATEROL/GLYCOPYRRONIUM (IND/GLY) REDUCES THE RISK OF CLINICALLY IMPORTANT DETERIORATION (CID) VERSUS SALMETEROL/FLUTICASONE (SFC): THE FLAME STUDY
    Wedzicha, Jadwiga A.
    Anzueto, Antonio R.
    Kostikas, Konstantinos
    Mezzi, Karen
    Fucile, Sebastian
    Bader, Giovanni
    Shen, Steven
    Banerji, Donald
    Fogel, Robert
    RESPIROLOGY, 2017, 22 : 178 - 178
  • [3] Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies
    Anzueto, Antonio R.
    Kostikas, Konstantinos
    Mezzi, Karen
    Fucile, Sebastian
    Bader, Giovanni
    Shen, Steven
    Banerji, Donald
    Fogel, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [4] Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis
    Anzueto, Antonio R.
    Kostikas, Konstantinos
    Mezzi, Karen
    Fucile, Sebastian
    Bader, Giovanni
    Shen, Steven
    Banerji, Donald
    Fogel, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [5] Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
    Greulich, Timm
    Kostikas, Konstantinos
    Gaga, Mina
    Aalamian-Mattheis, Maryam
    Lossi, Nadine S.
    Patalano, Francesco
    Nunez, Xavier
    Pagano, Veronica A.
    Fogel, Robert
    Vogelmeier, Claus F.
    Clemens, Andreas
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 1229 - 1237
  • [6] Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients
    Demin, Ivan
    Bartels, Christian
    Graham, Gordon
    Bieth, Bruno
    Gautier, Aurelie
    Tillmann, Hanns-Christian
    Sechaud, Romain
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (06) : 405 - 415
  • [7] Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
    Anzueto, Antonio R.
    Kostikas, Konstantinos
    Mezzi, Karen
    Shen, Steven
    Larbig, Michael
    Patalano, Francesco
    Fogel, Robert
    Banerji, Donald
    Wedzicha, Jadwiga A.
    RESPIRATORY RESEARCH, 2018, 19
  • [8] Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
    Antonio R. Anzueto
    Konstantinos Kostikas
    Karen Mezzi
    Steven Shen
    Michael Larbig
    Francesco Patalano
    Robert Fogel
    Donald Banerji
    Jadwiga A. Wedzicha
    Respiratory Research, 19
  • [9] Single Inhaler Extrafine Triple Therapy Reduces Clinically Important Deterioration (CID) in COPD Compared to Indacaterol/Glycopyrronium: Post-Hoc Analysis of the TRIBUTE Study
    Scuri, M.
    Singh, D.
    Fabbri, L. M.
    Guasconi, A.
    Vezzoli, S.
    Prunier, H.
    Muraro, A.
    Petruzzelli, S.
    Papi, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [10] INDACATEROL/GLYCOPYRRONIUM (IND/GLY) IS SUPERIOR TO SALMETEROL/FLUTICASONE (SFC) IN ASIAN PATIENTS WITH MODERATE-TO-VERY SEVERE COPD AT A HIGH RISK OF EXACERBATIONS: FLAME STUDY RESULTS
    Wedzicha, J. A.
    Zhong, N.
    Ichinose, M.
    Larbig, M.
    Humphries, M.
    Fogel, R.
    Thach, C.
    Patalano, F.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 180 - 180
12345